Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy.
暂无分享,去创建一个
S. Morris | T. Cooper | A. Awad | H. You | Ting Gao | Hanning You | Alaa S. Awad
[1] S. Morris,et al. Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementation. , 2014, American journal of physiology. Renal physiology.
[2] R. Harris,et al. Role of Endothelial Nitric Oxide Synthase in Diabetic Nephropathy: Lessons from Diabetic eNOS Knockout Mice , 2014, Journal of diabetes research.
[3] R. Harris,et al. Renal endothelial dysfunction in diabetic nephropathy. , 2014, Cardiovascular & hematological disorders drug targets.
[4] T. Cooper,et al. Macrophages directly mediate diabetic renal injury. , 2013, American journal of physiology. Renal physiology.
[5] J. Pollock,et al. Renal Collecting Duct NOS1 Maintains Fluid–Electrolyte Homeostasis and Blood Pressure , 2013, Hypertension.
[6] S. Morris,et al. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism , 2013, Kidney international.
[7] K. Connelly,et al. eNOS deficiency predisposes podocytes to injury in diabetes. , 2012, Journal of the American Society of Nephrology : JASN.
[8] R. Harris,et al. Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice , 2012, Kidney international.
[9] Songming Huang,et al. Progress in Pathogenesis of Proteinuria , 2012, International journal of nephrology.
[10] E. Abdel-Rahman,et al. Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches , 2012, Journal of General Internal Medicine.
[11] R. Harris,et al. Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice. , 2012, American journal of physiology. Renal physiology.
[12] M. Okusa,et al. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. , 2011, American journal of physiology. Renal physiology.
[13] S. Morris,et al. Arginase-2 Mediates Diabetic Renal Injury , 2011, Diabetes.
[14] Hyung-Suk Kim,et al. A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy , 2011, Proceedings of the National Academy of Sciences.
[15] S. Giunti,et al. Targeting the MCP-1/CCR2 System in diabetic kidney disease. , 2010, Current vascular pharmacology.
[16] L. Juncos,et al. Salt-sensitive splice variant of nNOS expressed in the macula densa cells. , 2010, American journal of physiology. Renal physiology.
[17] C. Alpers,et al. Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[18] P. Krishan,et al. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[19] S. Morris. Arginine metabolism: boundaries of our knowledge. , 2007, The Journal of nutrition.
[20] M. Gannon,et al. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. , 2007, The American journal of pathology.
[21] B. Croker,et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. , 2007, Journal of the American Society of Nephrology : JASN.
[22] K. Kashiwagi,et al. Polyamines in renal failure , 2006, Amino Acids.
[23] H. Lovell,et al. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. , 2006, The Cochrane database of systematic reviews.
[24] E. Ritz,et al. Nephron number and renal risk in hypertension and diabetes. , 2005, Journal of the American Society of Nephrology : JASN.
[25] R. Komers,et al. Paradoxes of nitric oxide in the diabetic kidney. , 2003, American journal of physiology. Renal physiology.
[26] F. Cuccurullo,et al. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. , 2001, Free radical biology & medicine.
[27] K. Matsushima,et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. , 2000, Kidney international.
[28] H. Ovadia,et al. Renal nitric oxide production during the early phase of experimental diabetes mellitus. , 2000, Kidney international.
[29] S. Shin,et al. Neuronal and endothelial nitric oxide synthase expression in outer medulla of streptozotocin-induced diabetic rat kidney , 2000, Diabetologia.
[30] P. Ortiz de Montellano,et al. AMP‐activated protein kinase phosphorylation of endothelial NO synthase , 1999, FEBS letters.
[31] Guoyao Wu,et al. Arginine metabolism: nitric oxide and beyond. , 1998, The Biochemical journal.
[32] D. Kang,et al. Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. , 1997, Kidney international. Supplement.
[33] S. Morris,et al. Human type II arginase: sequence analysis and tissue-specific expression. , 1997, Gene.
[34] J. Vockley,et al. Cloning and characterization of the human type II arginase gene. , 1996, Genomics.
[35] M. Takiguchi,et al. Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage‐like cell line , 1996, FEBS letters.
[36] J. Warren,et al. Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. , 1996, Kidney international.
[37] S. Yagihashi,et al. Expression of nitric oxide synthase in macula densa in streptozotocin diabetic rats , 1996, Diabetologia.
[38] P. Tipping,et al. Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[39] L. Raijman,et al. Channeling of urea cycle intermediates in situ in permeabilized hepatocytes. , 1989, The Journal of biological chemistry.
[40] V. Wright,et al. CAPTOPRIL: A NEW TREATMENT FOR RHEUMATOID ARTHRITIS? , 1984, The Lancet.
[41] M. Cooper,et al. Mechanisms of diabetic complications. , 2013, Physiological reviews.
[42] Haifeng Guo,et al. US Renal Data System 2012 Annual Data Report. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[43] B. Croker,et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy , 2011, Nature Reviews Nephrology.
[44] C. Baylis. Nitric oxide deficiency in chronic kidney disease. , 2008, American journal of physiology. Renal physiology.
[45] R. Harris,et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. , 2006, Journal of the American Society of Nephrology : JASN.
[46] G. Bartosz,et al. Antioxidant and prooxidant properties of captopril and enalapril. , 1997, Free radical biology & medicine.
[47] P. Tipping,et al. Glomerular interleukin 1 production is dependent on macrophage infiltration in anti-GBM glomerulonephritis. , 1991, Kidney international.